Published in Am J Pathol on August 01, 2006
Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature (2012) 3.83
CDK4: A Key Player in the Cell Cycle, Development, and Cancer. Genes Cancer (2012) 1.07
Loss of nuclear receptor RXRα in epidermal keratinocytes promotes the formation of Cdk4-activated invasive melanomas. Pigment Cell Melanoma Res (2010) 0.88
Biology of MET: a double life between normal tissue repair and tumor progression. Ann Transl Med (2015) 0.86
Animal models of melanoma: a somatic cell gene delivery mouse model allows rapid evaluation of genes implicated in human melanoma. Chin J Cancer (2011) 0.79
Phorbol ester-induced neutrophilic inflammatory responses selectively promote metastatic spread of melanoma in a TLR4-dependent manner. Oncoimmunology (2015) 0.77
Animal Models of Uveal Melanoma: Methods, Applicability, and Limitations. Biomed Res Int (2016) 0.75
The epidermal polarity protein Par3 is a non-cell autonomous suppressor of malignant melanoma. J Exp Med (2017) 0.75
Genetically engineered mouse models of melanoma. Cancer (2017) 0.75
Deletion of ADAM-9 in HGF/CDK4 mice impairs melanoma development and metastasis. Oncogene (2017) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 14.30
Management of cutaneous melanoma. N Engl J Med (2004) 9.52
Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat Genet (1999) 8.53
Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature (2001) 7.06
Essential role for oncogenic Ras in tumour maintenance. Nature (1999) 6.51
Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature (1986) 6.14
A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (1995) 5.46
Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res (2003) 4.03
Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature (2001) 3.57
Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet (1996) 2.96
Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat Med (2002) 2.58
Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev (1997) 2.47
The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer (2003) 2.28
Neonatal sunburn and melanoma in mice. Nature (2001) 2.25
Invasive growth: from development to metastasis. J Clin Invest (2002) 1.91
Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res (2005) 1.84
Malignant melanoma: modern black plague and genetic black box. Genes Dev (1998) 1.67
Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene (2001) 1.59
Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescence. Mol Cell Biol (2002) 1.58
Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. Br J Cancer (1993) 1.55
c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res (1998) 1.54
Melanoma genetics and the development of rational therapeutics. J Clin Invest (2005) 1.50
Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res (2001) 1.43
Ink4a/arf deficiency promotes ultraviolet radiation-induced melanomagenesis. Cancer Res (2002) 1.24
Invasive melanoma in Cdk4-targeted mice. Proc Natl Acad Sci U S A (2001) 1.24
Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma. Int J Cancer (2000) 1.06
Hyperpigmentation and melanocytic hyperplasia in transgenic mice expressing the human T24 Ha-ras gene regulated by a mouse tyrosinase promoter. Mol Carcinog (1995) 1.03
Pathways to melanoma development: lessons from the mouse. J Invest Dermatol (2002) 1.02
Invasive growth: a genetic program. Int J Dev Biol (2004) 0.98
Induction of melanoma in TPras transgenic mice. Carcinogenesis (1999) 0.95
Signaling networks in cutaneous melanoma metastasis identified by complementary DNA microarrays. Arch Dermatol (2005) 0.95
Hepatocyte growth factor induces redistribution of p21(CIP1) and p27(KIP1) through ERK-dependent p16(INK4a) up-regulation, leading to cell cycle arrest at G1 in HepG2 hepatoma cells. J Biol Chem (2005) 0.93
Evaluation of premalignant and malignant lesions during the induction of mouse melanomas. Cancer Res (1987) 0.91
Genetic immunization with a melanocytic self-antigen linked to foreign helper sequences breaks tolerance and induces autoimmunity and tumor immunity. Gene Ther (2002) 0.90
Evaluation of genetic melanoma vaccines in cdk4-mutant mice provides evidence for immunological tolerance against authochthonous melanomas in the skin. Int J Cancer (2006) 0.76
Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer (2009) 11.25
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med (2011) 11.01
Tumour biology: senescence in premalignant tumours. Nature (2005) 10.15
RAS oncogenes: the first 30 years. Nat Rev Cancer (2003) 8.61
LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature (2005) 8.53
Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell (2007) 8.47
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39
Mammalian cyclin-dependent kinases. Trends Biochem Sci (2005) 5.54
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell (2003) 5.17
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet (2003) 4.74
Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell (2011) 4.49
Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell (2004) 4.39
Cdk1 is sufficient to drive the mammalian cell cycle. Nature (2007) 4.26
Bats host major mammalian paramyxoviruses. Nat Commun (2012) 4.15
A pericyte origin of spinal cord scar tissue. Science (2011) 4.12
Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell (2008) 4.01
A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell (2010) 3.97
Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol (2007) 3.89
The European dimension for the mouse genome mutagenesis program. Nat Genet (2004) 3.84
Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature (2012) 3.83
Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta (2002) 3.77
AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood (2009) 3.65
Interferon-γ links ultraviolet radiation to melanomagenesis in mice. Nature (2011) 3.56
Genomic stability and tumour suppression by the APC/C cofactor Cdh1. Nat Cell Biol (2008) 3.31
p38alpha MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat Genet (2007) 3.30
Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest (2002) 3.24
5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med (2008) 3.13
Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res (2006) 3.00
Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med (2014) 2.92
Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med (2004) 2.90
Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing. Immunity (2013) 2.79
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A (2009) 2.77
MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer (2008) 2.76
Retracted Cytohesins are cytoplasmic ErbB receptor activators. Cell (2010) 2.74
Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res (2009) 2.65
Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res (2006) 2.62
Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol (2012) 2.59
EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell (2012) 2.59
Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat Med (2002) 2.58
Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell (2011) 2.56
Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis (2009) 2.54
Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation. Nat Cell Biol (2007) 2.50
Cell cycle kinases in cancer. Curr Opin Genet Dev (2007) 2.46
Control of cell proliferation pathways by microRNAs. Cell Cycle (2008) 2.33
c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell (2011) 2.28
Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells. Cancer Cell (2009) 2.28
The two faces of interferon-γ in cancer. Clin Cancer Res (2011) 2.20
Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition. Cancer Cell (2008) 2.12
Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nat Biotechnol (2010) 2.11
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol (2011) 2.10
The Cdc14B phosphatase displays oncogenic activity mediated by the Ras-Mek signaling pathway. Cell Cycle (2011) 2.10
Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood (2007) 2.05
Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF. PLoS One (2009) 2.03
Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4. Nature (2010) 2.01
Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol (2009) 1.99
Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood (2013) 1.98
CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci (2007) 1.95
A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy. Carcinogenesis (2007) 1.95
Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proc Natl Acad Sci U S A (2006) 1.93
Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction amplitude and cell fate through CRAF. Sci Signal (2011) 1.90
Melanoma induction by ultraviolet A but not ultraviolet B radiation requires melanin pigment. Nat Commun (2012) 1.90
Cdh1 regulates osteoblast function through an APC/C-independent modulation of Smurf1. Mol Cell (2011) 1.87
Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature (2011) 1.87
Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest (2009) 1.83
MicroRNAs and the cell cycle. Biochim Biophys Acta (2011) 1.81
Cyclin-dependent kinases: a family portrait. Nat Cell Biol (2009) 1.80
What we have learned about pancreatic cancer from mouse models. Gastroenterology (2012) 1.78
Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). Cancer Cell (2005) 1.78
A polymorphism in IRF4 affects human pigmentation through a tyrosinase-dependent MITF/TFAP2A pathway. Cell (2013) 1.75
Clear cell sarcoma-like tumor with osteoclast-like giant cells in the small bowel: further evidence for a new tumor entity. Int J Surg Pathol (2005) 1.74
Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology (2011) 1.73
The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus. EMBO J (2002) 1.72
Attenuation of allergic contact dermatitis through the endocannabinoid system. Science (2007) 1.70
Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol (2006) 1.68
Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J (2010) 1.66
Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res (2012) 1.65
Targeting mitotic exit leads to tumor regression in vivo: Modulation by Cdk1, Mastl, and the PP2A/B55α,δ phosphatase. Cancer Cell (2010) 1.63
AAV-mediated gene therapy for choroideremia: preclinical studies in personalized models. PLoS One (2013) 1.62
Genetic rescue of Cdk4 null mice restores pancreatic beta-cell proliferation but not homeostatic cell number. Oncogene (2003) 1.62
Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol (2005) 1.62
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer (2013) 1.61
ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc Natl Acad Sci U S A (2007) 1.61
Peripheral CD8+ T cell tolerance against melanocytic self-antigens in the skin is regulated in two steps by CD4+ T cells and local inflammation: implications for the pathophysiology of vitiligo. J Invest Dermatol (2005) 1.60
Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma. Carcinogenesis (2005) 1.59
Ultraviolet B but not ultraviolet A radiation initiates melanoma. Cancer Res (2004) 1.57
Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med (2013) 1.56
A catalyst for change: the European cancer Patient's Bill of Rights. Oncologist (2014) 1.55